BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38285742)

  • 1. A Case of Pituitary Apoplexy Following Leuprolide Injection for Prostate Cancer.
    Kim KW; Chee S; Sunkara N; Baker MH
    R I Med J (2013); 2024 Feb; 107(2):7-9. PubMed ID: 38285742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pituitary apoplexy induced by gonadotropin-releasing hormone (GnRH) agonist administration for treatment of prostate cancer: a systematic review.
    Raj R; Elshimy G; Jacob A; Arya PVA; Unnikrishnan DC; Correa R; Myint ZW
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2337-2347. PubMed ID: 34156518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pituitary apoplexy following gonadotropin-releasing hormone agonist administration with gonadotropin-secreting pituitary adenoma.
    Sasagawa Y; Tachibana O; Nakagawa A; Koya D; Iizuka H
    J Clin Neurosci; 2015 Mar; 22(3):601-3. PubMed ID: 25455737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary Apoplexy After Initial Leuprolide Injection.
    Fabiano AJ; George S
    World Neurosurg; 2016 Nov; 95():616.e7-616.e9. PubMed ID: 27586180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary apoplexy after leuprolide.
    Davis A; Goel S; Picolos M; Wang M; Lavis V
    Pituitary; 2006; 9(3):263-5. PubMed ID: 16832587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment.
    Tanios G; Mungo NA; Kapila A; Bajaj K
    BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28710301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case.
    Huang TY; Lin JP; Lieu AS; Chen YT; Chen HS; Jang MY; Shen JT; Wu WJ; Huang SP; Juan YS
    World J Surg Oncol; 2013 Oct; 11():254. PubMed ID: 24088191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary apoplexy after leuprolide administration for carcinoma of the prostate.
    Morsi A; Jamal S; Silverberg JD
    Clin Endocrinol (Oxf); 1996 Jan; 44(1):121-4. PubMed ID: 8706284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new?
    Faustini-Fustini M
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):378. PubMed ID: 9156052
    [No Abstract]   [Full Text] [Related]  

  • 10. The presence of a pituitary tumor in patients with prostate cancer is not a contraindication for leuprolide therapy.
    Babbo A; Kalapurakal GT; Liu B; Bajramovic S; Chandler JP; Garnett J; Kalapurakal JA
    Int Urol Nephrol; 2014 Sep; 46(9):1775-8. PubMed ID: 24705727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late onset of pituitary apoplexy following gonadotropin-releasing hormone agonist for prostate cancer treatment.
    Elshimy G; Raj R; Jacob A; Correa R
    BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35256375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer.
    Guerra Y; Lacuesta E; Marquez F; Raksin PB; Utset M; Fogelfeld L
    Pituitary; 2010; 13(1):54-9. PubMed ID: 19842040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropin-releasing hormone agonist-induced pituitary apoplexy in treatment of prostate cancer: case report and review of literature.
    Hands KE; Alvarez A; Bruder JM
    Endocr Pract; 2007 Oct; 13(6):642-6. PubMed ID: 17954421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer.
    Reznik Y; Chapon F; Lahlou N; Deboucher N; Mahoudeau J
    J Endocrinol Invest; 1997 Oct; 20(9):566-8. PubMed ID: 9413812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Two cases of non-functional gonadotroph adenoma pituitary apoplexy following GnRH-agonist treatment revealing gonadotroph adenoma and pseudopituitary apoplexy after GnRH administration].
    Hernandez Morin N; Huet D; Hautecouverture M
    Ann Endocrinol (Paris); 2003 Jun; 64(3):227-31. PubMed ID: 12910066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pituitary apoplexy after leuprolide injection for ovum donation.
    Engel G; Huston M; Oshima S; Beck C; Harsh G; Rosenthal MH; Camargo CA
    J Adolesc Health; 2003 Jan; 32(1):89-93. PubMed ID: 12507807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary apoplexy induced by gonadotropin-releasing hormone agonist administration: a rare complication of prostate cancer treatment.
    Barbosa M; Paredes S; Machado MJ; Almeida R; Marques O
    Endocrinol Diabetes Metab Case Rep; 2020 Jun; 2020():. PubMed ID: 32554827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary apoplexy induced by triptorelin in patient with prostate cancer.
    Guerrero-PĂ©rez F; Marengo AP; Planas-Vilaseca A; Flores-Escobar V; Villabona-Artero C
    Endocrinol Nutr; 2015 Oct; 62(8):411-2. PubMed ID: 26184059
    [No Abstract]   [Full Text] [Related]  

  • 19. Delayed pituitary apoplexy in patient with advanced prostate cancer treated with gonadotrophin-releasing hormone agonists.
    Sinnadurai M; Cherukuri RK; Moses RG; Nasser E
    J Clin Neurosci; 2010 Sep; 17(9):1201-3. PubMed ID: 20605467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.